Moderna, Inc. (MRNA)
Last updated: 2026-10-20 19:20:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Moderna, Inc. (MRNA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $240.64, with a market capitalization of $87.04B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $22.28 to $242.78. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$87.04B | |
$226.03 | |
$1,420.00 | |
$7.10 | |
$226.89 | |
12.99M | |
19.56M | |
-- | |
$242.78 | |
$22.28 | |
-- | |
2001-12-30 |
Moderna, Inc. (MRNA) Stock Price Today
Moderna, Inc. (MRNA) is currently trading at $240.64 as of 2026-10-20 19:05:00, up 6.06% ($13.75) from the previous close of $226.89
During today's regular trading session, MRNA has traded between $7.10 and $1,420.00, with a trading volume of 12.99M shares. The current price is near the lower end of today's range.
Moderna, Inc. (MRNA) 7-Day Stock Price Change
Over the past seven days, Moderna, Inc. (MRNA) moved from $225.00 to $240.64, representing a gain of 6.95% ($15.63).
The stock traded between $197.17 and $242.78 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 18.48 million shares, down versus the previous seven-day period, indicating lower trading activity.
MRNA 52-Week Price Position
Position in Range: 99.0%
MRNA is currently trading at $240.64, placing it 99.0% of the way from its 52-week low of $22.28 to its 52-week high of $242.78. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Moderna, Inc. (MRNA)?
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Moderna, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 4700 |
| CEO | Stéphane Bancel |
| Founded | 2010 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Moderna, Inc. (MRNA) Stock on MEXC
Eligible investors can buy real shares of Moderna, Inc. (MRNA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Moderna, Inc. (MRNA) stock price today?
2.Is MRNA stock going up or down today?
3.What is MRNA pre-market price?
4.What is MRNA after-hours price?
5.Is MRNA stock trading now?
6.Where does MRNA sit relative to its 52-week high and low?
7.What sector is Moderna, Inc. in?
8.What is Moderna, Inc.'s market capitalization and where is it listed?
9.How is MRNA valued in terms of P/E ratio and EPS?
10.Does Moderna, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
MRNA Stock Calculator
Estimate the value between MRNA shares and USD.
MRNA Shares to USD
1.00 MRNA shares = 240.635 USD
Calculations are estimates based on the latest available price and are for reference only.


